Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025194 · ClinicalTrials.gov registry record · Phase 1
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00025194: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00025194 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025194, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether BMS-247550 is more effective with or without estramustine in treating prostate cancer. PURPOSE: This randomized phase I/II trial is studying the best dose of ixabepilone when given together with estramustine and to see how well giving ixabepilone together with estramustine works compared to ixabepilone alone in treating patients with progressive prostate cancer.
Interventions
- DRUG ixabepilone
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025194
The ClinicalTrials.gov registry entry for NCT00025194 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ixabepilone is the first listed.
NCT00025194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025194 about?
NCT00025194 is a clinical study titled "Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether BMS-247550 is more effective with or without estramustine in treating prostate cancer. PURPOSE: This randomized ...
What is the current status of trial NCT00025194?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-07. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00025194?
The interventions under investigation include: ixabepilone (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00025194?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.